Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Isis Pharmaceuticals

Related ISIS
Benzinga's Top Initiations
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS) and raised its price target from $12.00 to $17.00.

BMO Capital Markets noted, “We are reiterating our Outperform rating on shares of ISIS and increasing our price target to $17 following our meeting with management. With the near-term focus on the KYNAMRO PDUFA, we are increasingly confident in approval and believe that upside potential extends beyond the initial commercial opportunity and to validation of an emerging late-stage pipeline. Relative to the value of KYNAMRO in HoFH, estimated at an NPV of $3/share, we believe that pipeline value is considerably greater, with an estimated NPV of $14/share, primarily driven by only 1 of 25 programs in the ASO for ApoCIII for triglycerides.”

Isis Pharmaceuticals closed on Friday at $13.28.

Latest Ratings for ISIS

Sep 2015BarclaysInitiates Coverage onEqual-weight
Jun 2015NeedhamReiteratesBuy
Jun 2015JP MorganMaintainsNeutral

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (ISIS)

Get Benzinga's Newsletters